Payment overview · 2025
General Payments
$1,908.07
115 reported records · 25 companies
Healthcare provider profile · identity verified
Natalie Inge Johnson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TYLER, TX · NPI 1356351977
Verified facts
What the public records show
CMS Open Payments records show Natalie Inge Johnson, M.D. received $1,908.07 in general payments during 2025 across 115 reported records.
ABBVIE INC. accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $366.90 | 19.2% | 26 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $257.29 | 13.5% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $248.28 | 13.0% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $165.61 | 8.7% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $159.05 | 8.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $134.32 | 7.0% | 10 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $67.05 | 3.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.99 | 3.1% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $47.39 | 2.5% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.92 | 2.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.37 | 2.0% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.01 | 1.9% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.33 | 1.8% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $33.31 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.72 | 1.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.32 | 1.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $27.69 | 1.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.74 | 1.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.73 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.80 | 0.9% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $16.53 | 0.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.06 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.34 | 0.8% | 1 | 2025 |
| Next Science LLC | Unresolved — no canonical attribution shown | $15.04 | 0.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.28 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,908.07 | 115 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $186.74 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $176.09 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $171.58 | 14 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $165.61 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $144.88 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $139.26 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.92 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $120.22 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.33 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $118.03 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $103.48 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.48 | 8 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $67.05 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.96 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.99 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $47.39 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.92 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $33.33 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $33.31 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.72 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $30.84 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.32 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| BlastX Normalized: blastx |
Device | Next Science LLC | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| Xperience Normalized: xperience |
Device | Next Science LLC | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 157 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 130 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 32 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 186 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 86 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
160 | 41 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
130 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
186 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
86 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1300 | 326 |
| Atorvastatin Calcium | Atorvastatin Calcium | 994 | 296 |
| Amlodipine Besylate | Amlodipine Besylate | 810 | 230 |
| Losartan Potassium | Losartan Potassium | 539 | 174 |
| Gabapentin | Gabapentin | 519 | 145 |
| Montelukast Sodium | Montelukast Sodium | 513 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 483 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 462 | 135 |
| Furosemide | Furosemide | 386 | 114 |
| Omeprazole | Omeprazole | 383 | 111 |
| Potassium Chloride | Potassium Chloride | 353 | 98 |
| Lisinopril | Lisinopril | 351 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 349 | 107 |
| Metformin Hcl | Metformin Hcl | 346 | 102 |
| Meloxicam | Meloxicam | 338 | 113 |
| Pravastatin Sodium | Pravastatin Sodium | 321 | 101 |
| Zolpidem Tartrate | Zolpidem Tartrate | 319 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 93 |
| Carvedilol | Carvedilol | 274 | 76 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 273 | 106 |
| Alprazolam | Alprazolam | 257 | 59 |
| Glimepiride | Glimepiride | 248 | 66 |
| Cephalexin | Cephalexin | 245 | 173 |
| Bupropion Xl | Bupropion Hcl | 244 | 65 |
| Tramadol Hcl | Tramadol Hcl | 240 | 63 |
| Sertraline Hcl | Sertraline Hcl | 233 | 65 |
| Trazodone Hcl | Trazodone Hcl | 229 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 223 | 55 |
| Fluoxetine Hcl | Fluoxetine Hcl | 213 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 187 | 56 |
| Ozempic | Semaglutide | 186 | 35 |
| Simvastatin | Simvastatin | 181 | 54 |
| Azithromycin | Azithromycin | 180 | 147 |
| Celecoxib | Celecoxib | 179 | 44 |
| Baclofen | Baclofen | 175 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 52 |
| Allopurinol | Allopurinol | 163 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 55 |
| Synthroid | Levothyroxine Sodium | 160 | 41 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 158 | 35 |
| Eliquis | Apixaban | 157 | 28 |
| Famotidine | Famotidine | 155 | 51 |
| Lorazepam | Lorazepam | 146 | 43 |
| Topiramate | Topiramate | 146 | 32 |
| Ezetimibe | Ezetimibe | 144 | 52 |
| Temazepam | Temazepam | 137 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 136 | 38 |
| Clonazepam | Clonazepam | 130 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 34 |
| Jardiance | Empagliflozin | 130 | 37 |
| Methylprednisolone | Methylprednisolone | 125 | 108 |
| Buspirone Hcl | Buspirone Hcl | 124 | 31 |
| Memantine Hcl | Memantine Hcl | 124 | 39 |
| Metformin Hcl Er | Metformin Hcl | 115 | 33 |
| Spironolactone | Spironolactone | 112 | 31 |
| Estradiol | Estradiol | 111 | 36 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 31 |
| Alendronate Sodium | Alendronate Sodium | 103 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 102 | 47 |
| Pregabalin | Pregabalin | 101 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 94 | 23 |
| Mirtazapine | Mirtazapine | 92 | 28 |
| Rybelsus | Semaglutide | 86 | 19 |
| Donepezil Hcl | Donepezil Hcl | 85 | 37 |
| Clonidine Hcl | Clonidine Hcl | 83 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 83 | 70 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 80 | 17 |
| Mounjaro | Tirzepatide | 77 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 75 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 23 |
| Atenolol | Atenolol | 71 | 25 |
| Methocarbamol | Methocarbamol | 71 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 16 |
| Farxiga | Dapagliflozin Propanediol | 69 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 21 |
| Irbesartan | Irbesartan | 68 | 18 |
| Cefdinir | Cefdinir | 67 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 24 |
| Prednisone | Prednisone | 63 | 20 |
| Carisoprodol | Carisoprodol | 62 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 62 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 16 |
| Trulicity | Dulaglutide | 61 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 20 |
| Ondansetron Odt | Ondansetron | 60 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 51 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Xarelto | Rivaroxaban | 59 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 18 |
| Fluconazole | Fluconazole | 57 | 47 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 16 |
| Valacyclovir | Valacyclovir Hcl | 56 | 26 |
| Glipizide Er | Glipizide | 55 | 14 |
| Diazepam | Diazepam | 53 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 22 |
| Januvia | Sitagliptin Phosphate | 52 | 11 |
| Valsartan | Valsartan | 52 | 18 |
| Doxepin Hcl | Doxepin Hcl | 51 | 19 |
| Glipizide | Glipizide | 51 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 41 |
| Levofloxacin | Levofloxacin | 50 | 44 |
| Fenofibrate | Fenofibrate | 48 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 15 |
| Lovastatin | Lovastatin | 47 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Myrbetriq | Mirabegron | 43 | 11 |
| Ibuprofen | Ibuprofen | 42 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 18 |
| Chlorthalidone | Chlorthalidone | 40 | 11 |
| Benazepril Hcl | Benazepril Hcl | 38 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 38 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Ramipril | Ramipril | 35 | 11 |
| Enalapril Maleate | Enalapril Maleate | 34 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Verapamil Er | Verapamil Hcl | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Linzess | Linaclotide | 32 | 13 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | 17 |
| Lamotrigine | Lamotrigine | 30 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 25 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Minoxidil | Minoxidil | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Nystatin | Nystatin | 23 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Np Thyroid | Thyroid,pork | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Zaleplon | Zaleplon | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 19 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 16 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Thyroid | Thyroid,pork | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,908.07 · 115 records | ABBVIE INC. | AIRSUPRA, AUSTEDO XR, BREZTRI, BlastX, CAPLYTA, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GEMTESA, Heplisav-B, JARDIANCE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, QUTENZA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAQEL, Veozah, Wegovy, XIFAXAN, Xperience, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error